Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
Fan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie He(First Affiliated Hospital of Jinan University), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Kang Shao(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Qiu(Shandong Academy of Agricultural Sciences), Wei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Li J(Zhejiang Medicine (China)), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Zhao(Linyi City Chinese Medicine Hospital), Fang Lv(Liaoning Normal University), Shuhang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 74
Related Papers
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|944
Cancer registration in China and its role in cancer prevention and control
|The Lancet Oncology|2020|501
The duck genome and transcriptome provide insight into an avian influenza virus reservoir species
|Nature Genetics|2013|460